Redeye: Acconeer should still be on your radar (updated post-Q3 version)

This is an updated version of our initiating coverage report from last week. We have made negligible revisions in our 2018 estimates related to short-term cost assumptions where we now expect an EBIT of SEK -35m (-39m) for 2018. Other than that the rest of the initial report, our estimates, valuation and investment case etc. are exactly the same and just as relevant as the first version.

Download the research update: http://bit.ly/2RdAdU7 

Start following companies at Redeye to recieve the latest research withtin Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/